Free tool
FAERS Monitor: Sodium Iodide I 123
Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations
Reports naming NDA 018671 or its brand name (Sodium Iodide I 123, Sodium Iodide I-123). Reports on generic versions are filed under their own applications.
Reports
940
Serious
896
95% of reports
Hospitalization
63
Death reported
45
Any cause; not necessarily from the drug
Most reported reactions
MedDRA preferred terms.
- hypothyroidism384
- endocrine ophthalmopathy36
- treatment failure26
- acute myeloid leukaemia24
- dacryostenosis acquired24
- parathyroid tumour benign21
- abortion spontaneous20
- hyperthyroidism20
- hyperparathyroidism19
- lacrimation increased19
- breast cancer17
- maternal exposure during pregnancy17
- thyroid cancer17
- nausea16
- sialoadenitis16
Reports by year received
View as table
| Year | Reports |
|---|---|
| 2005 | 1 |
| 2006 | 1 |
| 2007 | 33 |
| 2008 | 76 |
| 2009 | 56 |
| 2010 | 56 |
| 2011 | 263 |
| 2012 | 173 |
| 2013 | 82 |
| 2014 | 14 |
| 2015 | 17 |
| 2016 | 13 |
| 2017 | 5 |
| 2018 | 26 |
| 2019 | 48 |
| 2020 | 13 |
| 2021 | 48 |
| 2022 | 8 |
| 2024 | 3 |
| 2025 | 1 |
| 2026 | 3 |
Disproportionality screen
Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,053,219 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.
| Reaction | Reports | PRR | 95% CI lower | Chi-squared |
|---|---|---|---|---|
| endocrine ophthalmopathySignal | 36 | 969.1 | 698.5 | 32,452 |
| parathyroid tumour benignSignal | 21 | 652.3 | 424.7 | 12,646 |
| dacryostenosis acquiredSignal | 24 | 423.9 | 284.5 | 9,528 |
| hypothyroidismSignal | 384 | 272.4 | 252.0 | 102,458 |
| sialoadenitisSignal | 16 | 265.8 | 163.1 | 3,915 |
| hyperparathyroidismSignal | 19 | 208.2 | 133.1 | 3,679 |
| acute myeloid leukaemiaSignal | 24 | 34.5 | 23.2 | 747 |
| thyroid cancerSignal | 17 | 31.7 | 19.8 | 474 |
| hyperthyroidismSignal | 20 | 31.0 | 20.1 | 550 |
| lacrimation increasedSignal | 19 | 14.1 | 9.0 | 218 |
| abortion spontaneousSignal | 20 | 11.2 | 7.2 | 175 |
| treatment failureSignal | 26 | 7.0 | 4.8 | 129 |
| maternal exposure during pregnancySignal | 17 | 4.3 | 2.7 | 40 |
| breast cancerSignal | 17 | 4.1 | 2.5 | 37 |
| nausea | 16 | 0.5 | 0.3 | 10 |
A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.